CV Therapeutics' Selective Adenosine A1 Agonist Tecadenoson Shows Synergistic Effect with Ultra Low Dose Beta Blocker in Preclin
November 08 2007 - 8:00AM
PR Newswire (US)
PALO ALTO, Calif., Nov. 8 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today that data from a
preclinical study of the selective adenosine A1 agonist
tecadenoson, in combination with a low dose of the beta blocker
metoprolol, showed increased rate control compared to either agent
alone (p
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024
